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Background: The Spectra Optia (SPO) is a novel continuous-flow centrifugal apheresis 
system based on the COBE Spectra (CSP) platform. There have been few attempts to vali-
date the advantages of the SPO. We performed a retrospective study comparing the two 
cell separators for therapeutic plasma exchange (TPE) procedures in kidney transplant 
(KT) patients and seeing efficacy and safety.
Methods: We analyzed 720 TPE procedures performed between August 2012 and July 
2014. Procedures included desensitization TPE before KT and TPE for the management 
of acute and chronic antibody-mediated graft rejection. Demographic characteristics, op-
erational TPE variables, and laboratory data were analyzed.
Results: Demographic characteristics for the SPO (n=389) and CSP (n=331) groups did 
not differ significantly. The procedure time to exchange one plasma volume was 
94.2±10.3 min in the SPO group and 100.4±11.2 min in the CSP group (P <0.001). 
The plasma removal efficiency (PRE) was 92.5±4.9% in the SPO group and 83.2±3.7% 
in the CSP group (P <0.001). There were no significant differences across the two apher-
esis systems for changes in hematologic parameters.
Conclusions: Compared with the CSP, the SPO was associated with an improved PRE and 
a shorter procedure time to exchange one plasma volume. Our results in KT patients show 
that the SPO is superior to the CSP in TPE procedures.
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INTRODUCTION 
Despite previous limitations for solid organ transplantation due 
to ABO incompatibility, current medical practice has demon-
strated increasingly successful outcomes using therapeutic plas-
mapheresis. In Japan, ABO-incompatible kidney transplantation 
(ABOiKT) has been performed in more than 1,000 patients 
since 1989, and in recent years, it has accounted for approxi-
mately 18% of all living donor kidney transplants (KTs) [1]. As 
adjunct therapy, the routine use of rituximab, a monoclonal anti-
body directed against CD20 on B cells, has been shown to im-
prove clinical outcomes following ABOiKT. The clinical literature 
has repeatedly shown that outcomes following ABOiKT are com-
parable to those following ABO-compatible KT [2-5]. In all the 
published desensitization protocols before ABOiKT, recipients 
underwent 3-6 sessions of therapeutic plasma exchange (TPE) 
to reduce anti-A or anti-B titers. ABOiKT is currently an Ameri-
can Society for Apheresis Category II indication for TPE [6].
 Plasma exchange is performed by using automated devices 
designed with specialized instruments for blood withdrawal, an-
ticoagulation, separation, and blood return, as well as compart-
ments for replacement fluid and separated substances. The 
Spectra Optia (SPO) is a new continuous-flow centrifugal apher-
esis system developed by Terumo BCT (Tokyo, Japan) in 2007 
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that is based on the COBE Spectra (CSP) platform. It first be-
came available in Korea in 2012. The SPO incorporates an im-
proved automated interface management system, a graphical 
user interface, better data management with processing op-
tions, and simplified, ready-to-use tubing sets. Since the SPO 
was first introduced, two comparative analyses of the efficacy of 
plasmapheresis using the CSP and SPO were published [7, 8]. 
The trials compared efficacy and safety in each patient, using 
each machine in a paired, non-blinded clinical trial design. 
These studies indicated the superiority of the SPO, and con-
cluded that it was acceptable for regular use in clinical TPE. 
The studies were, however, limited by the small number of pa-
tients enrolled. In our study, we retrospectively compared TPE 
in KT patients using the SPO (n=389) and the CSP (n=331) 
on a larger scale in terms of efficacy and safety.
METHODS
1. Patient selection
We performed a retrospective analysis to compare TPE proce-
dures using the SPO and the CSP (Gambro BCT, Deerfield, IL, 
USA) at Severance Hospital (affiliated with Yonsei University 
Health System), Seoul, Korea. The TPE procedures were related 
to KT and included desensitization TPE for ABOiKT or lympho-
cyte crossmatch-positive KT and acute or chronic antibody-me-
diated graft rejection. The device was selected randomly for 
each procedure, not for each patient; thus, it was possible that 
patients underwent TPE with both devices, since each patient 
underwent multiple procedures. All procedures were performed 
between August 2012 and July 2014.
 A total of 720 procedures were reviewed; 389 used the SPO, 
and 331 used the CSP. There were no significant differences in 
patient characteristics, including sex, age, and weight. Clinical 
diagnoses for TPE in the SPO group were ABOiKT (n=98), lym-
phocyte crossmatch-positive KT (n=61), and antibody-medi-
ated rejection (n=230). In the CSP group, clinical diagnoses for 
TPE were ABOiKT (n=107), lymphocyte crossmatch-positive 
KT (n=40), and antibody-mediated rejection (n=184). There 
was no statistical differences in clinical diagnoses for TPE be-
tween the SPO and CSP groups  (Table 1). 
2. Study design
In all TPE procedures, acid citrate dextrose-A (ACD-A) anticoag-
ulation and dual vascular access were used, as previously de-
scribed [9]. The target volume of the procedure was 1.0 to 1.5 
plasma volumes (PV), which theoretically leads to approximately 
20-40% of the residual relative concentration [10]. One PV was 
removed from each patient, and 100% replacement was admin-
istered using 5% albumin and AB-blood group fresh frozen 
plasma (FFP). The inlet:anticoagulant ratio (concentration of an-
ticoagulant provided by the extracorporeal circuit) was 1:12 in 
the case of 5% albumin, and 1:15 in the case of FFP. All patients 
who underwent TPE were administered 1 ampule (10 mL) of 
10% calcium gluconate (Daihan Pham Co. Ltd, Seoul, Korea) to 
prevent hypocalcemia, which is one of the most common com-
plications of TPE [11-13]. After each procedure, the parameter 
shown in the result screen of the instrument, including whole 
blood flow rate, procedure time, PV processed, PV removed, 
used ACD volume, and infused ACD volume was recorded. Each 
patient’s blood was also sampled immediately before and after 
the TPE procedure. The complete blood count was determined 
by using the ADVIA 2120i (Siemens, Washington, D.C., USA). 
This study was carried out with approval from the Institutional 
Review Board of Yonsei University Health System.
3. Statistics and mathematical formulae
Statistical analysis was performed by using Microsoft Excel 
2010 (Microsoft Corporation, Richmond, WA, USA) and Anal-
yse-it (Analyse-it Software Ltd., Leeds, UK). The Shapiro-Wilk 
test was used to confirm a normal distribution. Pearson’s chi-
squared test and a two-sample t-test were employed to test sta-
tistical significance for demographic characteristics and TPE 
operational variables. P value<0.05 was considered statistically 
significant.
 To calculate total blood volume (TBV), we used Nadler’s 
equation [14]:
Table 1. Procedures and patient characteristics
Spectra Optia COBE Spectra P 
Procedures, N 389 331
Indication for TPE 0.073
   ABOiKT   98 107
   Antibody-mediated rejection 230 184
   LCM-positive KT   61   40
Sex, N (%) 0.407
   Female 54 (54) 46 (46)
   Male 67 (49) 71 (51)
Age (yr) 46.0±11.4 46.5±10.1 0.612
Weight (kg) 61.2±11.1 61.0±10.2 0.816
Abbreviations: TPE, therapeutic plasma exchange; ABOiKT, ABO-incompat-
ible kidney transplantation; LCM, lymphocyte crossmatch; KT, kidney trans-
plantation.
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 Male: 0.3669×Height3 +0.03219×Weight+0.6041
 Female: 0.3561×Height3 +0.03308×Weight+0.1833
The formula for plasma removal efficacy (PRE) used by Tormey 
et al. [7] was adapted for use in our study. PRE was calculated 
by using the following formula:
 %PRE=(PV processed/PV removed)×100%
RESULTS 
1. Plasma exchange performance
During TPE, 5,500±1,160 mL of plasma were processed in 
124.6 ±16.3 min using the SPO, and 5,646 ±1,298 mL of 
plasma were processed in 122.4±15.4 min using the CSP. We 
compared the time taken to achieve optimal therapeutic ex-
change of 1 PV between the two systems. The time required to 
exchange 1 PV was 94.2±10.3 min using the SPO compared 
with 100.4 ±11.2 min (P <0.001) using the CSP. PRE was 
92.5±4.9% using the SPO, compared with 83.2±3.7% using 
the CSP (P <0.001). The TBV processed, ACD-A volume uti-
lized, and PV processed in both groups showed no statistical 
differences (Table 2). 
2. Change in hematologic parameters pre- and post-TPE
Both groups showed non-significant post-procedural blood cell 
component losses, as compared with pre-procedure levels. 
White blood cell losses were comparable and low with use of 
both devices; there was a pre- to post-TPE white blood cell count 
difference of 0.66±2.1 (×109/L) with the SPO, and 0.56±2.2 
(×109/L) using the CSP. Changes in hemoglobin were non-sig-
nificant (SPO, 0.28±0.85 g/dL; CSP, -0.02±1.03 g/dL). Pre- 
and post-TPE platelet changes were also non-significant (SPO, 
-7.2±25.4 [×109/L]; CSP, -12.7±26 [×109/L]) (Table 3). 
DISCUSSION
The performance of two apheresis devices was compared in the 
setting of TPE procedures in KT recipients. Because the major 
goal for TPE is to remove plasma containing pathogenic sub-
stances, the time required to exchange 1 PV and PRE are im-
portant parameters for evaluating the performance of apheresis 
devices. Our results suggest that the SPO is more efficient for 
the removal of plasma, from the standpoint of time required for 
volume processing.
 In addition to performance-related parameters, patient out-
comes, such as post-TPE loss of blood cells, are also an impor-
tant consideration when comparing apheresis devices. Hequet 
et al. [8] showed less platelet loss using the SPO after TPE com-
pared with the CSP. Theoretically, a higher PRE may lead to 
lower platelet loss after TPE. However, our study did not show a 
statistical difference in platelet loss between the SPO and CSP.
 The SPO, unlike the CSP, shows the volume of infused ACD-
A to the patient during and after the procedure. During the TPE 
procedure, the most common side effect is hypocalcemia re-
lated to the presence of citrate, which chelates ionized calcium. 
In our study, the percentage of infused ACD-A volume to used 
ACD-A volume varied from 5.7% to 31.3%. Therefore, it is use-
ful to predict symptoms of hypocalcemia during the procedure 
Table 2. Comparison of plasma exchange performance between 
Spectra Optia and COBE Spectra 
Unit Spectra Optia COBE Spectra P 
WB flow rate mL/min 43.9±7.4 45.7±7.9 0.003
Procedure time min 124.6±16.3 122.4±15.4 0.068 
Time to exchange 1 PV min 94.2±10.3 100.4±11.2 <0.001
TBV processed mL 5,500±1,160 5,646±1298 0.112
ACD-A volume used mL 389±84 391±80 0.479
PV processed mL 3,815±763 3,921±827 0.074
PV removed mL 3,517±680 3,260±694 <0.001
Replacement fluid volume mL 3,027±617 2,884±627 0.002
Plasma removal efficiency % 92.5±4.9 83.2±3.7 <0.001
Removed ratio 1.14±0.15 1.06±0.18 <0.001
Data are expressed as mean±standard deviation.
Abbreviations: WB, whole blood; PV, plasma volume; TBV, total boold vol-
ume; ACD-A, acid citrate dextrose-A solution.
Table 3. Changes of hematologic parameters in patients pre- and 
post-TPE
Parameter Unit Spectra Optia COBE Spectra P 
WBC count ×109/L Pre- 7.2 ±2.8 7.2 ±2.9 0.900
Post- 8.0 ±3.1 7.8 ±3.1 0.850
Δ difference 0.66 ±2.1 0.56 ±2.2 0.782
Hemoglobin g/dL Pre- 10.2 ±1.4 10.0 ±1.8 0.501
Post- 10.5 ±1.7 10.0 ±2.0 0.118
Δ difference 0.28 ±0.85 -0.02 ±1.03 0.089
Hematocrit % Pre- 30.6 ±4.7 30.1 ±5.5 0.616
Post- 31.5 ±5.9 29.9 ±6.2 0.160
Δ difference 0.79 ±2.6 -0.16 ±3.3 0.094
Platelet count ×109/L Pre- 192.2 ±91.5 187.3 ±87.5 0.763
Post- 186.8 ±94.1 175.9 ±82.9 0.483
Δ difference -7.2 ±25.4 -12.7 ±26.0 0.229
Data are expressed as mean±standard deviation.
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and to decide if additional calcium replacement may be re-
quired after the procedure. Additionally, the SPO disposable kit 
does not require needle spiking to the saline bag, which again 
makes the SPO superior in terms of infection risk.
 Although this study is limited by the retrospective design, we 
believe that the large number of procedures evaluated in this 
study compensates for some biases. Our results parallel those 
of a previous clinical trial that used a non-blinded paired design 
[8]. In conclusion, the SPO is superior to the CSP in terms of 
time required to exchange 1 PV and PRE, has less extracorpo-
real volume, and is more user-friendly. Therefore, the SPO is a 
better option over the CSP for TPE procedures in KT patients.
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